Results from a standard PRISM assay using the PR1000 cell set showed INK4 overexpression (along with RB1 loss) to be among the top genomic alterations associated with resistance to CDK4/6 inhibition with Palbociclib. This paper also identified a new strategy to enhance inhibition of CDK4/6 kinases.
Menu
PRISM will be accepting submissions for our next screen May 27 – June 13!
DMSO-soluble small molecules (single agent and combination format) and single agent antibodies, ADCs, and growth-inhibiting cytokines will be accepted for our 930 cancer cell line screen.
